{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:18:06Z","timestamp":1775841486575,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.phrs.2023.106854","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T05:09:59Z","timestamp":1689570599000},"page":"106854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Novel application potential of cinaciguat in the treatment of mixed hyperlipidemia through targeting PTL\/NPC1L1 and alleviating intestinal microbiota dysbiosis and metabolic disorders"],"prefix":"10.1016","volume":"194","author":[{"given":"Ang","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renshuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jufeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106854_bib1","doi-asserted-by":"crossref","first-page":"16812","DOI":"10.1002\/jcp.28350","article-title":"Supriyo Chakraborty. A review on coronary artery disease, its risk factors, and therapeutics","volume":"234","author":"Malakar","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2023.106854_bib2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.15520\/jcmro.v4i03.405","article-title":"Gv Chanukya. Rosuvastatin and fenofibrate combination in the treatment of mixed hyperlipidemia: a narrative review","volume":"4","author":"Biswas","year":"2021","journal-title":"J. Curr. Med. Res. Opin."},{"key":"10.1016\/j.phrs.2023.106854_bib3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2174\/0929867327666200505091738","article-title":"Three musketeers for lowering cholesterol: statins, ezetimibe and evolocumab","volume":"28","author":"Xu","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvy029","article-title":"Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations","volume":"4","author":"Hall\u00e9n","year":"2018","journal-title":"Eur. Heart J. Cardiavasc. Pharmacother."},{"key":"10.1016\/j.phrs.2023.106854_bib5","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.2174\/0929867328666210222092628","article-title":"Lipid-lowering therapies for atherosclerosis: statins, fibrates, ezetimibe and pcsk9 monoclonal antibodies","volume":"28","author":"Ali","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.drudis.2007.07.024","article-title":"Pancreatic lipase inhibitors from natural sources: unexplored potential","volume":"12","author":"Birari","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2023.106854_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-pick c1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.106854_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrd1469","article-title":"Lipid metabolic enzymes: emerging drug targets for the treatment of obesity","volume":"3","author":"Shi","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2023.106854_bib9","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1021\/acs.jafc.6b04468","article-title":"Natural products with anti-obesity effects and different mechanisms of action","volume":"64","author":"Fu","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-pick c1-like 1 (npc1l1) protein in intestinal and hepatic cholesterol transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.phrs.2023.106854_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114111","article-title":"Niemann-pick c1-like 1 inhibitors for reducing cholesterol absorption","volume":"230","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113358","article-title":"One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and niemann-pick c1-like 1","volume":"216","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114766","article-title":"High throughput virtual screening (htvs) of peptide library: technological advancement in ligand discovery","volume":"243","author":"Tripathi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib14","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1021\/bi00009a003","article-title":"The 2.46 a resolution structure of the pancreatic lipase-colipase complex inhibited by a c11 alkyl phosphonate","volume":"34","author":"Egloff","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106854_bib15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1126\/sciadv.abb1989","article-title":"Menloparkcaunited Slac National Accelerator Lab. Cryo-em structures of npc1l1 reveal mechanisms of cholesterol transport and ezetimibe inhibition","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2023.106854_bib16","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1126\/sciadv.abg3188","article-title":"Structural insights into the mechanism of human npc1l1-mediated cholesterol uptake","volume":"7","author":"Hu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2023.106854_bib17","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1126\/sciadv.abh3997","article-title":"Structures of dimeric human npc1l1 provide insight into mechanisms for cholesterol absorption","volume":"7","author":"Long","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2023.106854_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"W Jia. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2023.106854_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gutjnl-2020-323071","article-title":"Gut microbiota-derived metabolites as central regulators in metabolic disorders","volume":"70","author":"Agus","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2023.106854_bib20","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1039\/D1FO03464B","article-title":"Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters","volume":"13","author":"Yan","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.phrs.2023.106854_bib21","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jnutbio.2015.07.019","article-title":"Gc\u2013tof-ms-based serum metabolomic investigations of naked oat bran supplementation in high-fat-diet-induced dyslipidemic rats","volume":"26","author":"Gu","year":"2015","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.phrs.2023.106854_bib22","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.3390\/foods11213325","article-title":"Effects of dietary tannic acid on obesity and gut microbiota in c57bl\/6j mice fed with high-fat diet","volume":"11","author":"Fang","year":"2022","journal-title":"Foods"},{"key":"10.1016\/j.phrs.2023.106854_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.675396","article-title":"Screening of anti-lipase components of artemisia argyi leaves based on spectrum-effect relationships and hplc-ms\/ms","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106854_bib24","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.3390\/molecules27196270","article-title":"First discovery of cholesterol-lowering activity of parthenolide as npc1l1 inhibitor","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.106854_bib25","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1021\/acs.jafc.2c00633","article-title":"Propionate ameliorates alcohol-induced liver injury in mice via the gut\u2013liver axis: focus on the improvement of intestinal permeability","volume":"70","author":"Xu","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128974","article-title":"Emodin lows npc1l1-mediated cholesterol absorption as an uncompetitive inhibitor","author":"Meng","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106854_bib27","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.3390\/molecules27217494","article-title":"Inhibitory effect of isoliquiritigenin in niemann-pick c1-like 1-mediated cholesterol uptake","volume":"27","author":"Zeng","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.106854_bib28","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1021\/acs.joc.2c02983","article-title":"Cytochalasans with inhibitory activity against npc1l1 from the endophytic fungus chaetomium nigricolor f5","volume":"88","author":"Gu","year":"2023","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.phrs.2023.106854_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2020.110305","article-title":"Inhibition of pancreatic lipase by environmental xenoestrogens","volume":"192","author":"Hu","year":"2020","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.phrs.2023.106854_bib30","doi-asserted-by":"crossref","first-page":"37166","DOI":"10.1038\/srep37166","article-title":"Merkely, T Radovits. Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload","volume":"6","author":"Bt Nemeth","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2023.106854_bib31","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1038\/s41598-017-10125-3","article-title":"Cinaciguat ameliorates glomerular damage by reducing erk1\/2 activity and tgf-ss expression in type-1 diabetic rats","volume":"7","author":"Czirok","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2023.106854_bib32","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1210\/en.2014-1343","article-title":"Soluble guanylate cyclase as a novel treatment target for osteoporosis","volume":"155","author":"Joshua","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2023.106854_bib33","unstructured":"Qi Zhao. Preventive effect of soluble guanglate cyclase activator cinaciguat in diabetes macrovasculopathy. Shandong University (Thesis for master degree). 2016."},{"key":"10.1016\/j.phrs.2023.106854_bib34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of npc1l1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2023.106854_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-021-27758-8","article-title":"Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion","volume":"13","author":"Hu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2023.106854_bib36","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1039\/D0FO03331F","article-title":"Effects of three different mannans on obesity and gut microbiota in high-fat diet-fed c57bl\/6j mice","volume":"12","author":"Song","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.phrs.2023.106854_bib37","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1039\/D1FO00126D","article-title":"Bidirectional interaction of nobiletin and gut microbiota in mice fed with a high-fat diet","volume":"12","author":"Zhang","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.phrs.2023.106854_bib38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bpg.2014.07.004","article-title":"Bile acids, obesity, and the metabolic syndrome","volume":"28","author":"Ma","year":"2014","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.phrs.2023.106854_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jff.2016.11.011","article-title":"Cholesterol-lowering effects of piceatannol, a stilbene from wine, using untargeted metabolomics","volume":"28","author":"Sham","year":"2017","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.phrs.2023.106854_bib40","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/iub.2073","article-title":"Familial combined hyperlipidemia: an overview of the underlying molecular mechanisms and therapeutic strategies","volume":"71","author":"Taghizadeh","year":"2019","journal-title":"Iubmb Life"},{"key":"10.1016\/j.phrs.2023.106854_bib41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejphar.2015.05.060","article-title":"Orlistat limits cholesterol intestinal absorption by niemann-pick c1-like 1 (npc1l1) inhibition","volume":"762","author":"Alqahtani","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106854_bib42","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1021\/ar3003267","article-title":"The increasingly complex mechanism of hmg-coa reductase","volume":"46","author":"Haines","year":"2013","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.phrs.2023.106854_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.abb.2017.06.001","article-title":"Hypercholesterolemia: the role of pcsk9","volume":"626","author":"Melendez","year":"2017","journal-title":"Arch. Biochem. Biophys. 625-"},{"key":"10.1016\/j.phrs.2023.106854_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105562","article-title":"New pcsk9 inhibitor mir-552-3p reduces ldl-c via enhancing ldlr in high fat diet-fed mice","volume":"167","author":"Ma","year":"2021","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823002104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823002104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:46:37Z","timestamp":1760913997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823002104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"alternative-id":["S1043661823002104"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106854","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel application potential of cinaciguat in the treatment of mixed hyperlipidemia through targeting PTL\/NPC1L1 and alleviating intestinal microbiota dysbiosis and metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106854"}}